MLAB (Mesa Laboratories) LT-Debt-to-Total-Asset : 0.25 (As of Dec. 2024)

View and export this data going back to 1995. Start your Free Trial

What is Mesa Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mesa Laboratories's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.25.

Mesa Laboratories's long-term debt to total assets ratio declined from Dec. 2023 (0.31) to Dec. 2024 (0.25). It may suggest that Mesa Laboratories is progressively becoming less dependent on debt to grow their business.

Mesa Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mesa Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesa Laboratories LT-Debt-to-Total-Asset Chart

Mesa Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.34

0.24

0.31

0.28

0.50

Mesa Laboratories Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.31	0.50	0.49	0.26	0.25

Mesa Laboratories LT-Debt-to-Total-Asset Calculation

Mesa Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	221.698	/	446.796
	=	0.50

Mesa Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	107.164	/	437.148
	=	0.25

Mesa Laboratories (NAS:MLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mesa Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mesa Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesa Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Hardware » Mesa Laboratories Inc (NAS:MLAB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MLI:Germany

Address

12100 West Sixth Avenue, Lakewood, CO, USA, 80228

Website

https://www.mesalabs.com

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

Executives

Gary M Owens	officer: COO	12100 W. 6TH AVENUE, LAKEWOOD CO 80228
Brian David Archbold	officer: SVP of Continuous Improvement	12100 W. 6TH AVENUE, LAKEWOOD CO 80228
John Bradley Schmieder	director	C/O MESA LABORATORIES, INC., 12100 W. 6TH AVENUE, LAKEWOOD CO 80228
John V Sakys	officer: VP Finance, CFO	MESA LABORATORIES, INC., 12100 W. 6TH AVENUE, LAKEWOOD CO 80228
Shannon Hall	director	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Evan Guillemin	director	380 LAFAYETTE STREET, SIXTH FLOOR, NEW YORK NY 10003
R Tony Tripeny	director	ONE RIVERFRONT PLAZA, CORNING NY 14831
Gregory Dinoia	officer: SVP Commercial Operations	12100 W. 6TH AVENUE, LAKEWOOD CO 80228
Mesa Laboratories Inc /co/	director	12100 W 6TH AVE, LAKEWOOD CO 80228
John James Sullivan	officer: VP Sales & Marketing	12100 W. 6TH AVENUE, LAKEWOOD CO 80228
David M Kelly	director
Shiraz Shabanali Ladiwala	director	C/O THERMO FISHER SCIENTIFIC INC., 168 THIRD AVENUE, WALTHAM MA 02451
Robert V Dwyer	director	12100 W 6TH AVE, LAKEWOOD CO 80228
Jennifer Sadie Alltoft	director	12100 W. 6TH AVENUE, LAKEWOOD CO 80228
David Brian Perez	director	12100 6TH AVENUE, LAKEWOOD CO 80228